Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00253526
Recruitment Status : Withdrawn
First Posted : November 15, 2005
Last Update Posted : April 28, 2015
Information provided by:
National Cancer Institute (NCI)

November 11, 2005
November 15, 2005
April 28, 2015
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00253526 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
Phase II Randomized Study of Surgical Resection and Adjuvant Gemcitabine Hydrochloride With Versus Without Bevacizumab in Patients With Adenocarcinoma of the Pancreas

RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells an help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of pancreatic cancer by blocking blood flow to the tumor. Giving gemcitabine hydrochloride together with bevacizumab after surgery may kill any remaining tumor cells.

PURPOSE: This phase II trial is studying gemcitabine hydrochloride and bevacizumab to see how well they work compared to gemcitabine hydrochloride alone in treating patients who are undergoing surgery for pancreatic cancer.



  • Compare the disease-free interval in patients with adenocarcinoma of the pancreas treated with surgical resection followed by adjuvant gemcitabine hydrochloride with vs without bevacizumab.


  • Compare overall survival in patients treated with these regimens.
  • Evaluate tumor gene expression profiles and levels of tumor angiogenesis markers to establish prognostic indicators for response in patients treated with these regimens.

OUTLINE: This is a randomized, controlled study.

All patients undergo surgical resection for the pancreatic tumor. Within 4-8 weeks after surgery, patients are stratified according to projected 2-year survival (≤ 5% vs > 5% and ≤ 33% vs > 33%). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive gemcitabine hydrochloride IV over 100 minutes on days 1, 8, and 15, and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses. Patients then receive bevacizumab IV alone every 2 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive gemcitabine hydrochloride IV over 100 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 130 patients will be accrued for this study.

Phase 2
Primary Purpose: Treatment
  • Adenocarcinoma of the Pancreas
  • Recurrent Pancreatic Cancer
  • Stage I Pancreatic Cancer
  • Stage II Pancreatic Cancer
  • Stage III Pancreatic Cancer
  • Drug: bevacizumab
  • Drug: gemcitabine hydrochloride
  • Procedure: adjuvant therapy
  • Procedure: anti-cytokine therapy
  • Procedure: antiangiogenesis therapy
  • Procedure: antibody therapy
  • Procedure: biological therapy
  • Procedure: chemotherapy
  • Procedure: conventional surgery
  • Procedure: growth factor antagonist therapy
  • Procedure: monoclonal antibody therapy
  • Procedure: surgery
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided
Not Provided


  • Histologically or cytologically confirmed adenocarcinoma of the pancreas
  • No evidence of distant metastasis on laparoscopy
  • No superior mesenteric artery or thrombosed superior mesenteric vein involvement
  • Superior mesenteric vein or portal vein involvement allowed
  • Evidence of a pancreatic mass by radiographic or endoscopic examination


Performance status

  • ECOG 0-1

Life expectancy

  • Not specified


  • WBC ≥ 2,500/mm^3
  • Absolute neutrophil count ≥ 1,250/mm^3
  • Platelet count ≥ 100,000/mm^3


  • Hepatitis B surface antigen negative
  • Hepatitis C virus negative
  • No history of hepatic cirrhosis


  • Creatinine ≤ 2.0 mg/dL
  • Proteinuria negative or trace by urinalysis OR
  • Protein < 1 g on 24 hr urine collection
  • No active gross hematuria


  • No severe congestive heart failure
  • No active ischemic heart disease
  • No ischemic changes on a cardiac thallium stress test
  • No uncontrolled hypertension (i.e., blood pressure ≤ 150/100 mm Hg despite antihypertensive therapy)
  • No active coagulation disorder


  • No active gross hemoptysis


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during the adjuvant therapy part of trial
  • HIV negative
  • No active infection
  • No wound healing problem from recent invasive procedure
  • No significant history of medical illness that would preclude patient from undergoing an operative procedure
  • No other malignancy requiring systemic therapy


Biologic therapy

  • Recovered from prior immunotherapy for pancreatic cancer
  • No prior bevacizumab


  • Recovered from prior chemotherapy for pancreatic cancer
  • No prior gemcitabine hydrochloride

Endocrine therapy

  • Recovered from prior hormonal therapy for pancreatic cancer


  • Recovered from prior radiotherapy for pancreatic cancer
  • No prior radiotherapy to the pancreas


  • No prior definitive resection of the primary pancreatic tumor
  • Prior surgery, other than resection of the primary tumor, allowed


  • More than 3 weeks since prior systemic therapy for this cancer
  • No concurrent therapeutic anticoagulation causing elevated PT or PTT
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
Not Provided
Not Provided
Not Provided
Not Provided
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Richard E. Royal, MD, FACS National Cancer Institute (NCI)
National Cancer Institute (NCI)
December 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP